论文部分内容阅读
对20例肥胖T2DM患者给予利拉鲁肽联合甘精胰岛素治疗12周,采用自身前后对照的方法,观察患者血糖、血脂(甘油三酯TG、胆固醇TC)、体重指数(BMI)C肽等指标的变化情况。治疗后空腹血糖(FPG)、餐后2小时血糖(2hPG)、BMI、甘油三酯TG、胆固醇TG水平均明显下降,而空腹C肽(F-CP)2hC肽(2h-CP)明显高于治疗前(P<0.01)。利拉鲁肽联合甘精胰岛素可有效控肥胖T2DM患者的血糖水平,改善胰岛B细胞功能,并降低体重。
Twenty patients with T2DM were given liraglutide combined with insulin glargine for 12 weeks. The patients’ blood glucose, blood lipid (triglyceride TG, cholesterol TC) and BMI C-peptide were observed by self-control before and after treatment. Changes in the situation. Fasting plasma glucose (FPG), postprandial 2-hour blood glucose (2hPG), BMI, triglyceride TG and cholesterol TG levels were significantly decreased after treatment, while fasting C-peptide 2hC peptide was significantly higher Before treatment (P <0.01). Liraglutide combined with insulin glargine can effectively control blood glucose levels in obese T2DM patients, improve pancreatic B cell function and reduce body weight.